216 related articles for article (PubMed ID: 21557634)
1. Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?
Chiriva-Internati M; Cobos E; Cannon MJ
Int Rev Immunol; 2011; 30(2-3):67-70. PubMed ID: 21557634
[TBL] [Abstract][Full Text] [Related]
2. Sperm protein 17: clinical relevance of a cancer/testis antigen, from contraception to cancer immunotherapy, and beyond.
Chiriva-Internati M
Int Rev Immunol; 2011; 30(2-3):138-49. PubMed ID: 21557640
[TBL] [Abstract][Full Text] [Related]
3. Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.
Chiriva-Internati M; Mirandola L; Kast WM; Jenkins MR; Cobos E; Cannon MJ
Int Rev Immunol; 2011; 30(2-3):71-86. PubMed ID: 21557635
[TBL] [Abstract][Full Text] [Related]
4. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
[TBL] [Abstract][Full Text] [Related]
5. Immunologic approaches to ovarian cancer treatment.
Sabbatini P; Odunsi K
J Clin Oncol; 2007 Jul; 25(20):2884-93. PubMed ID: 17617519
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer creates a suppressive microenvironment to escape immune elimination.
Yigit R; Massuger LF; Figdor CG; Torensma R
Gynecol Oncol; 2010 May; 117(2):366-72. PubMed ID: 20144842
[TBL] [Abstract][Full Text] [Related]
7. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
Santin AD; Bellone S; Underwood LJ; O'Brien TJ; Ravaggi A; Pecorelli S; Cannon MJ
Minerva Ginecol; 2002 Apr; 54(2):133-44. PubMed ID: 12032451
[TBL] [Abstract][Full Text] [Related]
8. Harnessing the immune system for ovarian cancer therapy.
Odunsi K; Sabbatini P
Am J Reprod Immunol; 2008 Jan; 59(1):62-74. PubMed ID: 18154597
[TBL] [Abstract][Full Text] [Related]
9. Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer.
Cannon MJ; O'Brien TJ; Underwood LJ; Crew MD; Bondurant KL; Santin AD
Expert Rev Anticancer Ther; 2002 Feb; 2(1):97-105. PubMed ID: 12113075
[TBL] [Abstract][Full Text] [Related]
10. Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer.
Chiriva-Internati M; Weidanz JA; Yu Y; Frezza EE; Jenkins MR; Kennedy RC; Cobos E; Kast WM
J Immunother; 2008 Oct; 31(8):693-703. PubMed ID: 18779750
[TBL] [Abstract][Full Text] [Related]
11. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
12. Immune therapy for ovarian cancer: promise and pitfalls.
Thibodeaux SR; Curiel TJ
Int Rev Immunol; 2011; 30(2-3):102-19. PubMed ID: 21557637
[TBL] [Abstract][Full Text] [Related]
13. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
14. On immunotherapies and cancer vaccination protocols: a mathematical modelling approach.
Joshi B; Wang X; Banerjee S; Tian H; Matzavinos A; Chaplain MA
J Theor Biol; 2009 Aug; 259(4):820-7. PubMed ID: 19446568
[TBL] [Abstract][Full Text] [Related]
15. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.
Sinnathamby G; Lauer P; Zerfass J; Hanson B; Karabudak A; Krakover J; Secord AA; Clay TM; Morse MA; Dubensky TW; Brockstedt DG; Philip R; Giedlin M
J Immunother; 2009 Oct; 32(8):856-69. PubMed ID: 19752748
[TBL] [Abstract][Full Text] [Related]
16. Increased ovarian tumor cell surface reacting antibodies in patients with ovarian adenocarcinoma after viral oncolysate treatment.
Ioannides CG; Platsoucas CD; Bowen JM; Wharton JT; Freedman RS
Anticancer Res; 1989; 9(1):81-6. PubMed ID: 2705759
[TBL] [Abstract][Full Text] [Related]
17. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
18. Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer.
Mirandola L; J Cannon M; Cobos E; Bernardini G; Jenkins MR; Kast WM; Chiriva-Internati M
Int Rev Immunol; 2011; 30(2-3):127-37. PubMed ID: 21557639
[TBL] [Abstract][Full Text] [Related]
19. Vaccination as a treatment for breast or ovarian cancer.
Holmberg LA; Sandmaier B
Expert Rev Vaccines; 2004 Jun; 3(3):269-77. PubMed ID: 15176943
[TBL] [Abstract][Full Text] [Related]
20. Current approaches in ovarian cancer vaccines.
Reinartz S; Wagner U
Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
